Search

Your search keyword '"Meynard, JL"' showing total 153 results

Search Constraints

Start Over You searched for: Author "Meynard, JL" Remove constraint Author: "Meynard, JL"
153 results on '"Meynard, JL"'

Search Results

1. Risk factors associated with 10% weight change in treatment-naïve and treatment-experienced people living with HIV initiating or switching to an NNRTI- or INSTI-based antiretroviral therapy in four large cohort studies

2. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

3. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

4. Outcomes in antiretroviral‐naive HIV‐infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

5. Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens

6. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

8. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 Substudy

15. Impact of Newly Available Drugs on Clinical Progression in Patients with Virological Failure after Exposure to Three Classes of Antiretrovirals

16. Impact of Insertions in the HIV-1 P6 Ptapp Region on the Virological Response to Amprenavir

17. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

18. Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

19. A HIV Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.

20. Human metapneumovirus infection is associated with a substantial morbidity and mortality burden in adult inpatients.

21. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.

22. Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort.

23. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study.

24. APOBEC-Induced Mutations at Initiation of Cabotegravir + Rilpivirine for Two Patients Infected by HIV-1 Subtype CRF02: The Interest of Systematic Genotyping.

26. Immune restoration therapy for multidrug-resistant CMV disease in an allogenic stem cell transplant recipient.

27. COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease.

28. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis.

29. Why are people still dying of drug-susceptible TB in Paris in the 21 st century?

30. Factors associated with tuberculosis-associated haemophagocytic syndrome: a multicentre case-control study.

31. Serum Tryptophan-Derived Quinolinate and Indole-3-Acetate Are Associated With Carotid Intima-Media Thickness and its Evolution in HIV-Infected Treated Adults.

32. Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).

33. INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.

34. Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status.

35. Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.

36. Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads.

37. Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France.

38. Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).

39. Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients.

40. Clinical and microbiological determinants of severe and fatal outcomes in patients infected with Enterobacteriaceae producing extended-spectrum β-lactamase.

41. Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?

42. Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study.

43. Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.

44. [Henoch-Schönlein purpura-like vasculitis revealing HIV infection].

46. Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen.

47. Clostridium difficile associated reactive arthritis: Case report and literature review.

48. Diversity and combinations of infectious agents in 38 adults with an infection-triggered reactive haemophagocytic syndrome: a multicenter study.

49. Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort.

50. Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.

Catalog

Books, media, physical & digital resources